Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey A Pfefferkorn

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|April 1, 2009
'Muscle-sparing' statins: preclinical profiles and future clinical useJeffrey A Pfefferkorn
Expert Opinion on Drug Discovery|January 8, 2013
Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetesJeffrey A Pfefferkorn
Expert Opinion on Therapeutic Patents|January 11, 2011
Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent reviewJeffrey A Pfefferkorn
Expert Opinion on Therapeutic Patents|May 14, 2014
A patent review of glucokinase activators and disruptors of the glucokinase--glucokinase regulatory protein interaction: 2011-2014Kevin J Filipski, Jeffrey A Pfefferkorn
Pharmaceutical Patent Analyst|November 19, 2013
Building structure-activity insights through patent miningMeihua Tu, Jeffrey A Pfefferkorn, Angel Guzman-Perez, et al.
Pharmaceutical Patent Analyst|November 19, 2013
Glucokinase activatorsKevin J Filipski, Kentaro Futatsugi, Jeffrey A Pfefferkorn, et al.
The Biochemical Journal|November 3, 2011
Modulation of glucokinase by glucose, small-molecule activator and glucokinase regulatory protein: steady-state kinetic and cell-based analysisFrancis J Bourbonais, Jing Chen, Cong Huang, et al.
Bioorganic & Medicinal Chemistry|January 9, 2003
Novel strategies for the solid phase synthesis of substituted indolines and indolesK C Nicolaou, A J Roecker, Robert Hughes, et al.
Plos One|January 13, 2017
Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma CellsJessica E C Jones, William P Esler, Rushi Patel, et al.
Clinical Pharmacology and Therapeutics|March 29, 2019
Effect of Hepatic Organic Anion-Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver-Targeted Glucokinase Activator: A Model-Based EvaluationArthur Bergman, Yi-An Bi, Sumathy Mathialagan, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Current Opinion in Investigational Drugs (London, England : 2000)|April 1, 2009
'Muscle-sparing' statins: preclinical profiles and future clinical useJeffrey A Pfefferkorn
Expert Opinion on Drug Discovery|January 8, 2013
Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetesJeffrey A Pfefferkorn
Expert Opinion on Therapeutic Patents|January 11, 2011
Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent reviewJeffrey A Pfefferkorn
Expert Opinion on Therapeutic Patents|May 14, 2014
A patent review of glucokinase activators and disruptors of the glucokinase--glucokinase regulatory protein interaction: 2011-2014Kevin J Filipski, Jeffrey A Pfefferkorn
Pharmaceutical Patent Analyst|November 19, 2013
Building structure-activity insights through patent miningMeihua Tu, Jeffrey A Pfefferkorn, Angel Guzman-Perez, et al.
Pharmaceutical Patent Analyst|November 19, 2013
Glucokinase activatorsKevin J Filipski, Kentaro Futatsugi, Jeffrey A Pfefferkorn, et al.
The Biochemical Journal|November 3, 2011
Modulation of glucokinase by glucose, small-molecule activator and glucokinase regulatory protein: steady-state kinetic and cell-based analysisFrancis J Bourbonais, Jing Chen, Cong Huang, et al.
Bioorganic & Medicinal Chemistry|January 9, 2003
Novel strategies for the solid phase synthesis of substituted indolines and indolesK C Nicolaou, A J Roecker, Robert Hughes, et al.
Plos One|January 13, 2017
Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma CellsJessica E C Jones, William P Esler, Rushi Patel, et al.
Clinical Pharmacology and Therapeutics|March 29, 2019
Effect of Hepatic Organic Anion-Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver-Targeted Glucokinase Activator: A Model-Based EvaluationArthur Bergman, Yi-An Bi, Sumathy Mathialagan, et al.
Pageof 6